Go To Main TNBC Website


  New Posts New Posts RSS Feed - GOOD NEWS: 10 year survival with metastatic BC up
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

GOOD NEWS: 10 year survival with metastatic BC up

 Post Reply Post Reply
Author
dmwolf View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jan 22 2009
Location: Berkeley, CA
Status: Offline
Points: 3619
Post Options Post Options   Thanks (0) Thanks(0)   Quote dmwolf Quote  Post ReplyReply Direct Link To This Post Topic: GOOD NEWS: 10 year survival with metastatic BC up
    Posted: Jan 14 2011 at 10:01pm

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

MD Anderson study finds increases in 5-, 10-year survival at every stage of breast cancer

VIDEO: This study finds higher survival rate at every stage of breast cancer.

Click here for more information.

HOUSTON - Advances in screening for disease detection, better surgical techniques available to more women, and an increased number of therapies that reduce the risk of relapse in patients with both locally advanced and early stage disease, have collectively contributed to dramatic improvements in breast cancer's survival rates, according to a review of 60 years of patient records at The University of Texas MD Anderson Cancer Center.

The single institution study found increases in both five and 10-year survival at every stage of the disease in every decade studied. Aman Buzdar, M.D., professor in MD Anderson's Department of Breast Medical Oncology presented the data in advance of the 2010 Breast Cancer Symposium.

Similar to that of the National Cancer Institute's (NCI) Surveillance, Epidemiology and End Results Program (SEER), MD Anderson's Department of Breast Medical Oncology has maintained a comprehensive database collecting information on incidence, prevalence and mortality since the institution's inception almost 70 years ago. MD Anderson is in a unique position in that it has the largest group in the country, perhaps in the world, committed to the treatment of breast cancer, explains Buzdar.

"The concept of combined, multi-disciplinary approach for the management of breast cancer care, and that of other cancers, was introduced early on and remains the cornerstone of our care," says Buzdar, the study's senior author. "At MD Anderson, new therapeutic advances have long-been incorporated into the clinical care of patients early-on, resulting in improved survival of patients within each stage of disease. Over the years, with the discovery of research milestones, we have published studies looking at MD Anderson patients to determine how these discoveries have impacted their survival."

For this retrospective, single-institution study, Buzdar and his team reviewed records of 56,864 breast cancer patients seen at MD Anderson between 1944 and 2004. Of those, 12,809 women had their initial therapy at the institution. For each decade, patients were determined to have one of three stages of disease: local, regional and distant, or metastatic.

Across the decades, the researchers looked at five and 10-year survival by stage, both of which were calculated from the date of initial presentation. From decade to decade, the researchers found an impressive increase in survival in all three stages of the disease, as well as overall survival:

Years Percent survival at 10 years (number of patients)
Local Disease Regional Disease Distant Disease Overall*
1944-54 55.0% (120) 16.2% (191) 3.3% (92) 25.1% (410)
1955-64 56.0% (462) 23.9% (656) 4.0% (306) 30.5% (1,449)
1965-74 59.3% (440) 28.8% (566) 4.7% (321) 34.6% (1,387)
1975-84 72.0% (701) 46.9% (828) 7.4% (367) 49.3% (1,983)
1985-94 78.5% (1,036) 57.4% (1,268) 11.2% (364) 61.6% (2,927)
1995-04 86.1% (1,898) 74.1% (1,569) 22.2% (455) 76.5% (4,653)
*Also includes patients with in situ or unknown stages of the disease

Buzdar notes the improved survival in metastatic patients of great significance as these patients have disease that may not be curable, yet a significant proportion of these patients can now live for a number of years with available therapies.

"In the first decade we tracked, 1944-1954, the 10-year survival of women with metastatic breast cancer was just 3.3 percent. However, between the decades of 1985-1994 and 1995-2004, the survival gain in the same cohort increased from 11.2 to 22.2 percent, respectively. This dramatic shift is a true testament to not only breast cancer's overall research and clinical milestones - improved chemotherapies, addition of new drugs, improvement of endocrine therapies and more recently biologics - but to the appropriate and disciplined approach and utilization of these therapies," says Buzdar.

A number of MD Anderson's research milestones have impacted clinical care and breast cancer survival, both at the institution, and beyond, says Buzdar, including: combined modality approach to the treatment of the disease; utilization of systemic therapies prior to surgery; refinement of chemotherapies, specifically the incorporation of anthracyclines, taxanes and biologics, and newer hormonal agents like aromatase inhibitors.

While these research milestones and study findings are obviously encouraging, still more needs to be done, he says.

"Now, we need to turn our attention to the refinement of breast cancer therapies, with a goal of further decreasing risk of recurrence and death for our high-risk early stage breast cancer patients, and maintaining the control of disease in those with metastatic disease," says Buzdar.


DX 2/08@43 stg II IDC; gr2,0 nodes. Neoadj chemo, first ACx2 (fail) then CarboTaxotereX6(better). Lump, Rads done 11/08; Clodronate. False alarm queen: PetCT lung & TM marker. NED. PBM w/recon 9/10.
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12568
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Jan 15 2011 at 1:28am
Thanks Denise.  I'd like to think his last sentence is directed towards Triple Negative BC.

Donna
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
TNBC_in_NS View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jul 26 2009
Location: NS Canada
Status: Offline
Points: 2028
Post Options Post Options   Thanks (0) Thanks(0)   Quote TNBC_in_NS Quote  Post ReplyReply Direct Link To This Post Posted: Jan 15 2011 at 9:10am
Yes, they have come a long way with the positive receptor cancers, and this is good!
The last sentence is for us, the high-risk cancer, so hopefully they will get to work and find therapies for us!
Thanks Denise!
Hugs, h.
Diag@57TNBC04/092.5cm Lquad 05/09 TCx4Radsx30CT03/01/10 FU03/31/10ClearBRCA- 01/2011 RTNBC BMX 06/14/2011~2013 clear
Back to Top
dmwolf View Drop Down
Senior Member
Senior Member
Avatar

Joined: Jan 22 2009
Location: Berkeley, CA
Status: Offline
Points: 3619
Post Options Post Options   Thanks (0) Thanks(0)   Quote dmwolf Quote  Post ReplyReply Direct Link To This Post Posted: Jan 15 2011 at 12:16pm
Helen, these results apply to TNs too, at least looking at local and regional disease.    I don't know what share of the improvement in stageIV's is for TNs.  Probably the lion's share is ER+ and Her2+, but I bet we're in there too.
d
DX 2/08@43 stg II IDC; gr2,0 nodes. Neoadj chemo, first ACx2 (fail) then CarboTaxotereX6(better). Lump, Rads done 11/08; Clodronate. False alarm queen: PetCT lung & TM marker. NED. PBM w/recon 9/10.
Back to Top
 Post Reply Post Reply
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.